X0303 4 2009-11-24 0 0000891293 CELL THERAPEUTICS INC CTIC 0001201041 LOVE RICHARD L 501 ELLIOTT AVE WEST SUITE 400 SEATTLE WA 98119 1 0 0 0 Common Stock 2009-11-24 4 A 0 653690 A 1511112 D In August 2009 and as reported in a Form 8-K filed by CTI with the SEC on August 7, 2009, CTI entered into a second amendment to the acquisition agreement whereby CTI acquired Systems Medicine Inc. (SMI) in a stock-for-stock merger in July 2007. Pursuant to the second amendment, certain earn-out provisions of the acquisition agreement were removed, subject to the approval of CTI's shareholders and provided that CTI pay SMI stockholders (including Richard Love) a substitute payment based on their pro rata ownership of SMI prior to the acquisition. The substitute payment, if approved by CTI's shareholders, would be in the form of CTI common stock. The substitute payment arrangement was approved by CTI's shareholders on October 20, 2009. These shares represent the substitute payment made to Mr. Love pursuant to the second amendment. Louis A. Bianco, Attorney-in-fact for Richard L. Love 2009-11-24